These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients. Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517 [TBL] [Abstract][Full Text] [Related]
4. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies. Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250 [TBL] [Abstract][Full Text] [Related]
5. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells. Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984 [TBL] [Abstract][Full Text] [Related]
6. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease. Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451 [TBL] [Abstract][Full Text] [Related]
7. Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse. Park JL; Shu L; Shayman JA Am J Physiol Heart Circ Physiol; 2009 Apr; 296(4):H1133-40. PubMed ID: 19202000 [TBL] [Abstract][Full Text] [Related]
8. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630 [TBL] [Abstract][Full Text] [Related]
9. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease. Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087 [TBL] [Abstract][Full Text] [Related]
10. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females. Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857 [TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-mediated suppression of A4GALT rescues endothelial cell dysfunction in a fabry disease vasculopathy model derived from human induced pluripotent stem cells. Shin YJ; Chae SY; Lee H; Fang X; Cui S; Lim SW; Lee KI; Lee JY; Li C; Yang CW; Chung BH Atherosclerosis; 2024 Oct; 397():118549. PubMed ID: 39141976 [TBL] [Abstract][Full Text] [Related]
12. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling. Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584 [TBL] [Abstract][Full Text] [Related]
14. Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease. Modrego A; Amaranto M; Godino A; Mendoza R; Barra JL; Corchero JL Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204583 [TBL] [Abstract][Full Text] [Related]
15. Human kidney organoids reveal the role of glutathione in Fabry disease. Kim JW; Kim HW; Nam SA; Lee JY; Cho HJ; Kim TM; Kim YK Exp Mol Med; 2021 Oct; 53(10):1580-1591. PubMed ID: 34654880 [TBL] [Abstract][Full Text] [Related]
16. Fabry disease: GLA deletion alters a canonical splice site in a family with neuropsychiatric manifestations. Varela P; Carvalho G; Martin RP; Pesquero JB Metab Brain Dis; 2021 Feb; 36(2):265-272. PubMed ID: 33156427 [TBL] [Abstract][Full Text] [Related]
17. Restoration of peripheral neuropathy in Fabry mice via intrathecal administration of an adeno-associated virus vector encoding mGLA cDNA. Higuchi T; Shimada Y; Takahashi Y; Kato F; Ohashi T; Kobayashi H Mol Genet Metab; 2024; 143(1-2):108545. PubMed ID: 39068683 [TBL] [Abstract][Full Text] [Related]
18. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease. Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513 [TBL] [Abstract][Full Text] [Related]
19. Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease. Tuttolomondo A; Baglio I; Riolo R; Todaro F; Parrinello G; Miceli S; Simonetta I Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203231 [TBL] [Abstract][Full Text] [Related]